Helix BioPharma Corp. (OTCMKTS:HBPCF – Get Free Report) fell 11.6% during mid-day trading on Tuesday . The company traded as low as $0.65 and last traded at $0.65. 2,900 shares traded hands during trading, an increase of 136% from the average session volume of 1,228 shares. The stock had previously closed at $0.74.
Helix BioPharma Price Performance
The stock’s 50-day moving average is $0.86 and its 200-day moving average is $0.40. The stock has a market cap of $159.32 million, a price-to-earnings ratio of -32.50 and a beta of 0.02.
About Helix BioPharma
Helix BioPharma Corp. operates as an immune-oncology company in Canada. It is developing L-DOS47 for the treatment of non-small cell lung cancer; and V-DOS47 that targets the vascular epithelial growth factor receptor 2. Helix BioPharma Corp. has collaboration agreements with Moffitt Cancer Center to investigate the pharmacodynamics of L-DOS47 and determine the benefits of combining L-DOS47 with immune checkpoint inhibitors; and with University Hospital Tuebingen to assess the therapeutic response of L-DOS47 in cancer models expressing CEACAM6, with advanced preclinical metabolic imaging.
Featured Stories
- Five stocks we like better than Helix BioPharma
- What is a buyback in stocks? A comprehensive guide for investors
- Is McDonald’s Stock a Smart Buy After Sell-Off and Earnings?
- How to Calculate Options Profits
- QuantumScape: Solid State EV Batteries Nearing Commercialization
- 3 Stocks to Protect Your Portfolio from the Coronavirus Contagion
- MicroStrategy: Is This Bitcoin-Powered Stock a Buy or a Gamble?
Receive News & Ratings for Helix BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Helix BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.
